Leerink Partners Reiterates Outperform Rating on Axsome Therapeutics (AXSM)

December 30, 2024 3:00 PM UTC Send to a Friend
Leerink Partners analyst Marc Goodman reiterated an Outperform rating and $110.00 price target on Axsome Therapeutics (NASDAQ: AXSM).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login